TY - JOUR
T1 - Tercer Consenso Nacional de Cáncer de Ovario 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"
AU - Gallardo-Rincón, Dolores
AU - Cantú-de-León, David
AU - Alanís-López, Patricia
AU - Álvarez-Avitia, Miguel Ángel
AU - Bañuelos-Flores, Joel
AU - Herbert-Núñez, Guillermo Sidney
AU - Oñate-Ocaña, Luis Fernando
AU - Pérez-Montiel, María Delia
AU - Rodríguez-Trejo, Amelia
AU - Ruvalcaba-Limón, Eva
AU - Serrano-Olvera, Alberto
AU - Ortega-Rojo, Andrea
AU - Cortés-Esteban, Patricia
AU - Erazo-Valle, Aura
AU - Gerson-Cwilich, Raquel
AU - De-la-Garza-Salazar, Jaime
AU - Green-Renner, Dan
AU - León-Rodríguez, Eucario
AU - Morales-Vásquez, Flavia
AU - Poveda-Velasco, Andrés
AU - Aguilar-Ponce, José Luis
AU - Alva-López, Luis Felipe
AU - Alvarado-Aguilar, Salvador
AU - Alvarado-Cabrero, Isabel
AU - Aquino-Mendoza, Cinthia Alejandra
AU - Aranda-Flores, Carlos Eduardo
AU - Bandera-Delgado, Artfy
AU - Barragán-Curiel, Eduardo
AU - Barrón-Rodríguez, Patricia
AU - Brom-Valladares, Rocío
AU - Cabrera-Galeana, Paula Anel
AU - Calderillo-Ruiz, Germán
AU - Camacho-Gutiérrez, Salvador
AU - Capdeville-García, Daniel
AU - Cárdenas-Sánchez, Jesús
AU - Carlón-Zárate, Elisa
AU - Carrillo-Garibaldi, Óscar
AU - Castorena-Roji, Gerardo
AU - Cervantes-Sánchez, Guadalupe
AU - Coronel-Martínez, Jaime Alberto
AU - Chanona-Vilchis, José Gregorio
AU - Díaz-Hernández, Verónica
AU - Escudero-De-Los Ríos, Pedro
AU - Garibay-Cerdenares, Olga
AU - Gómez-García, Eva
AU - Herrera-Montalvo, Luis Alonso
AU - Hinojosa-García, Luz María
AU - Isla-Ortiz, David
AU - Jiménez-López, Josefina
AU - Lavín-Lozano, Arturo Javier
AU - Limón-Rodríguez, Jesús Alberto
AU - López-Basave, Horacio Noé
AU - López-García, Sergio César
AU - Maffuz-Aziz, Antonio
AU - Martínez-Cedillo, Jorge
AU - Martínez-López, Dulce María
AU - Medina-Castro, Juan Manuel
AU - Melo-Martínez, Carlos
AU - Méndez-Herrera, Carmen
AU - Montalvo-Esquivel, Gonzalo
AU - Morales-Palomares, Miguel Ángel
AU - Morán-Mendoza, Andrés
AU - Morgan-Villela, Gilberto
AU - Mota-García, Aída
AU - Muñoz-González, David Eduardo
AU - Ochoa-Carrillo, Francisco J.
AU - Pérez-Amador, Maricruz
AU - Recinos-Money, Edgar
AU - Rivera-Rivera, Samuel
AU - Robles Flores, Juan U.
AU - Rojas-Castillo, Edith
AU - Rojas-Marín, Carlos
AU - Salas-Gonzáles, Efraín
AU - Sámano-Nateras, Liliana
AU - Santibañez-Andrade, Miguel
AU - Santillán-Gómez, Antonio
AU - Silva-García, Araceli
AU - Silva, Juan Alejandro
AU - Solorza-Luna, Gilberto
AU - Tabarez-Ortiz, Adán Raúl
AU - Talamás-Rohana, Patricia
AU - Tirado-Gómez, Laura Leticia
AU - Torres-Lobatón, Alfonso
AU - Quijano-Castro, Félix
PY - 2011/11
Y1 - 2011/11
N2 - Introduction. Ovarian cancer (OC) is the third most common gynecologic malignancy worldwide. Most of cases it is of epithelial origin. At the present time there is not a standardized screening method, which makes difficult the early diagnosis. The 5-year survival is 90% for early stages, however most cases present at advanced stages, which have a 5-year survival of only 5-20%. GICOM collaborative group, under the auspice of different institutions, have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia. Material and methods. The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of two days in which a debate was held. These statements are the conclusions reached by agreement of the participant members. Results. No screening method is recommended at the time for the detection of early lesions of ovarian cancer in general population. Staging is surgical, according to FIGO. In regards to the pre-surgery evaluation of the patient, it is recommended to perform chest radiography and CT scan of abdomen and pelvis with IV contrast. According to the histopathology of the tumor, in order to consider it as borderline, the minimum percentage of proliferative component must be 10% of tumor's surface. The recommended standardized treatment includes primary surgery for diagnosis, staging and cytoreduction, followed by adjuvant chemotherapy. Surgery must be performed by an Oncologist Gynecologist or an Oncologist Surgeon because inadequate surgery performed by another specialist has been reported in 75% of cases. In regards to surgery, it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10-30% of all cases, and systematic limphadenectomy, necessary to be able to obtain an adequate surgical staging. Fertility-sparing surgery will be performed in certain cases, the procedure should include a detailed inspection of the contralateral ovary and also negative for malignancy omentum and ovary biopsy. Until now, laparoscopy for diagnostic-staging surgery is not well known as a recommended method. The recommended chemotherapy is based on platin and taxanes for 6 cycles, except in Stage IA, IB and grade 1, which have a good prognosis. In advanced stages, primary cytoreduction is recommended as initial treatment. Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer. Radiotherapy can be used to palliate symptoms. Follow up of the patients every 2-4 months for 2 years, every 3-6 months for 3 years and anually after the 5th year is recommended. Evaluation of quality of life of the patient must be done periodically. Conclusions. In the present, there is not a standardized screening method. Diagnosis in early stages means a better survival. Standardized treatment includes primary surgery with the objective to perform an optimal cytoreduction followed by chemotherapy. Treatment must be individualized according to each patient. Radiotherapy can be indicated to palliate symptoms.
AB - Introduction. Ovarian cancer (OC) is the third most common gynecologic malignancy worldwide. Most of cases it is of epithelial origin. At the present time there is not a standardized screening method, which makes difficult the early diagnosis. The 5-year survival is 90% for early stages, however most cases present at advanced stages, which have a 5-year survival of only 5-20%. GICOM collaborative group, under the auspice of different institutions, have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia. Material and methods. The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of two days in which a debate was held. These statements are the conclusions reached by agreement of the participant members. Results. No screening method is recommended at the time for the detection of early lesions of ovarian cancer in general population. Staging is surgical, according to FIGO. In regards to the pre-surgery evaluation of the patient, it is recommended to perform chest radiography and CT scan of abdomen and pelvis with IV contrast. According to the histopathology of the tumor, in order to consider it as borderline, the minimum percentage of proliferative component must be 10% of tumor's surface. The recommended standardized treatment includes primary surgery for diagnosis, staging and cytoreduction, followed by adjuvant chemotherapy. Surgery must be performed by an Oncologist Gynecologist or an Oncologist Surgeon because inadequate surgery performed by another specialist has been reported in 75% of cases. In regards to surgery, it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10-30% of all cases, and systematic limphadenectomy, necessary to be able to obtain an adequate surgical staging. Fertility-sparing surgery will be performed in certain cases, the procedure should include a detailed inspection of the contralateral ovary and also negative for malignancy omentum and ovary biopsy. Until now, laparoscopy for diagnostic-staging surgery is not well known as a recommended method. The recommended chemotherapy is based on platin and taxanes for 6 cycles, except in Stage IA, IB and grade 1, which have a good prognosis. In advanced stages, primary cytoreduction is recommended as initial treatment. Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer. Radiotherapy can be used to palliate symptoms. Follow up of the patients every 2-4 months for 2 years, every 3-6 months for 3 years and anually after the 5th year is recommended. Evaluation of quality of life of the patient must be done periodically. Conclusions. In the present, there is not a standardized screening method. Diagnosis in early stages means a better survival. Standardized treatment includes primary surgery with the objective to perform an optimal cytoreduction followed by chemotherapy. Treatment must be individualized according to each patient. Radiotherapy can be indicated to palliate symptoms.
KW - Cancer
KW - Chemotherapy
KW - Ovarian
KW - Radiotherapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84859522051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859522051&partnerID=8YFLogxK
M3 - Article
C2 - 23650680
AN - SCOPUS:84859522051
SN - 0034-8376
VL - 63
SP - 665
EP - 702
JO - Revista de Investigacion Clinica
JF - Revista de Investigacion Clinica
IS - 6
ER -